middle.news
Nyrada Inc. Posts $2.46M Loss as NYR-BI03 Advances to First Human Trial
6:54am on Monday 2nd of June, 2025 AEST
•
Biotechnology
Read Story
Nyrada Inc. Posts $2.46M Loss as NYR-BI03 Advances to First Human Trial
6:54am on Monday 2nd of June, 2025 AEST
Key Points
Loss widened to $2.46 million from prior profit of $136K
Revenue declined 64% to $884,584 due to R&D focus
NYR-BI03 preclinical data shows strong neuro- and cardioprotection
Received ethics approval to commence Phase Ia clinical trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nyrada (ASX:NYR)
OPEN ARTICLE